Pamrevlumab
Pamrevlumab targeted the scar-like tissue around pancreatic tumours; its phase 3 LAPIS trial in locally advanced disease did not lengthen survival.
Overview
FibroGen developed pamrevlumab for fibrotic diseases and for pancreatic cancer, where connective tissue growth factor helps build the stroma that shields tumour cells. A phase 1/2 study suggested more patients could reach surgery.
The phase 3 LAPIS trial in locally advanced unresectable pancreatic cancer, combined with gemcitabine and nab-paclitaxel or FOLFIRINOX, did not meet its overall survival endpoint, reported in 2024. A metastatic arm within the Precision Promise platform trial was also stopped for futility, ending the programme.
Binds connective tissue growth factor, a driver of the dense fibrous stroma that surrounds pancreatic tumours, aiming to make them more resectable and more permeable to chemotherapy.
1.Pamrevlumab binds its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"Pamrevlumab" OR ABSTRACT:"Pamrevlumab" OR TITLE:"FG-3019" OR ABSTRACT:"FG-3019") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pamrevlumab, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyCD40 agonist antibodies
Shares Monoclonal antibodies, Pancreatic ductal adenocarcinoma.
- TrialNOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer)
Shares Monoclonal antibodies, Pancreatic ductal adenocarcinoma.
- IdeaBlock the complement signal that recruits tumour-protecting cells
Shares Monoclonal antibodies, Pancreatic ductal adenocarcinoma.
- TreatmentGemcitabine + nab-paclitaxel
Shares LAPIS, Pancreatic ductal adenocarcinoma.
- TreatmentFOLFIRINOX / mFOLFIRINOX
Shares LAPIS, Pancreatic ductal adenocarcinoma.
- IdeaReprogramme suppressive macrophages instead of trying to delete them
Shares Monoclonal antibodies, Pancreatic ductal adenocarcinoma.
- PersonEric Van Cutsem
Shares Monoclonal antibodies, Pancreatic ductal adenocarcinoma.
- IdeaCombine the new anti-wasting antibody with exercise and protein
Shares Monoclonal antibodies, Pancreatic ductal adenocarcinoma.